Wells Fargo’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$290M Buy
1,895,677
+53,634
+3% +$8.22M 0.05% 287
2025
Q4
$254M Buy
1,842,043
+12,199
+0.7% +$1.6M 0.05% 327
2025
Q3
$235M Sell
1,829,844
-33,424
-2% -$4.08M 0.04% 336
2025
Q2
$225M Sell
1,863,268
-32,693
-2% -$3.68M 0.05% 330
2025
Q1
$211M Sell
1,895,961
-1,610
-0.1% -$171K 0.05% 318
2024
Q4
$185M Sell
1,897,571
-86,276
-4% -$9.2M 0.04% 346
2024
Q3
$228M Sell
1,983,847
-104,727
-5% -$11.9M 0.05% 299
2024
Q2
$222M Buy
2,088,574
+78,448
+4% +$7.87M 0.05% 291
2024
Q1
$194M Buy
2,010,126
+6,578
+0.3% +$674K 0.05% 309
2023
Q4
$202M Sell
2,003,548
-5,631
-0.3% -$544K 0.05% 293
2023
Q3
$205M Sell
2,009,179
-53,871
-3% -$5.47M 0.06% 270
2023
Q2
$208M Sell
2,063,050
-97,661
-5% -$9.77M 0.06% 269
2023
Q1
$199M Buy
2,160,711
+12,795
+0.6% +$1.12M 0.06% 270
2022
Q4
$195M Sell
2,147,916
-169,269
-7% -$14.3M 0.06% 274
2022
Q3
$176M Sell
2,317,185
-311,335
-12% -$25.8M 0.06% 280
2022
Q2
$222M Sell
2,628,520
-456,224
-15% -$40M 0.07% 245
2022
Q1
$271M Sell
3,084,744
-81,300
-3% -$7.04M 0.07% 238
2021
Q4
$277M Sell
3,166,044
-2,149,285
-40% -$178M 0.07% 236
2021
Q3
$435M Sell
5,315,329
-80,504
-1% -$7.24M 0.1% 200
2021
Q2
$492M Sell
5,395,833
-416,666
-7% -$37.1M 0.11% 185
2021
Q1
$497M Sell
5,812,499
-540,304
-9% -$48.5M 0.11% 175
2020
Q4
$600M Sell
6,352,803
-219,999
-3% -$19.2M 0.14% 148
2020
Q3
$572M Sell
6,572,802
-1,836
-0% -$159K 0.16% 139
2020
Q2
$574M Sell
6,574,638
-66,643
-1% -$5.75M 0.17% 134
2020
Q1
$548M Sell
6,641,281
-107,723
-2% -$9.61M 0.19% 118
2019
Q4
$639M Buy
6,749,004
+35,100
+0.5% +$3.15M 0.17% 128
2019
Q3
$583M Buy
6,713,904
+20,818
+0.3% +$1.87M 0.17% 131
2019
Q2
$611M Sell
6,693,086
-2,050,141
-23% -$174M 0.17% 127
2019
Q1
$753M Sell
8,743,227
-52,918
-0.6% -$4.25M 0.22% 99
2018
Q4
$676M Buy
8,796,145
+248,368
+3% +$19.3M 0.22% 97
2018
Q3
$660M Sell
8,547,777
-109,850
-1% -$8.12M 0.19% 116
2018
Q2
$586M Sell
8,657,627
-96,129
-1% -$6.63M 0.17% 126
2018
Q1
$634M Sell
8,753,756
-34,786
-0.4% -$2.65M 0.19% 119
2017
Q4
$661M Buy
8,788,542
+1,542
+0% +$116K 0.19% 115
2017
Q3
$676M Buy
8,787,000
+157,059
+2% +$11.9M 0.21% 100
2017
Q2
$645M Sell
8,629,941
-1,526,553
-15% -$108M 0.21% 103
2017
Q1
$676M Buy
10,156,494
+1,102,944
+12% +$73.5M 0.22% 99
2016
Q4
$591M Buy
9,053,550
+686,641
+8% +$44.5M 0.21% 110
2016
Q3
$592M Buy
8,366,909
+7,878
+0.1% +$574K 0.22% 99
2016
Q2
$618M Buy
8,359,031
+133,476
+2% +$9.22M 0.24% 90
2016
Q1
$534M Sell
8,225,555
-26,874
-0.3% -$1.83M 0.21% 107
2015
Q4
$636M Sell
8,252,429
-235,597
-3% -$18.7M 0.25% 87
2015
Q3
$699M Sell
8,488,026
-134,058
-2% -$11.9M 0.29% 63
2015
Q2
$760M Buy
8,622,084
+133,263
+2% +$12.2M 0.29% 62
2015
Q1
$750M Buy
8,488,821
+27,264
+0.3% +$2.42M 0.29% 66
2014
Q4
$703M Buy
8,461,557
+216,177
+3% +$17.9M 0.28% 72
2014
Q3
$695M Buy
8,245,380
+363,505
+5% +$29.4M 0.29% 64
2014
Q2
$639M Buy
7,881,875
+132,836
+2% +$10.4M 0.26% 73
2014
Q1
$590M Sell
7,749,039
-187,675
-2% -$13.7M 0.25% 88
2013
Q4
$572M Sell
7,936,714
-195,762
-2% -$13.6M 0.25% 87
2013
Q3
$559M Sell
8,132,476
-18,990
-0.2% -$1.26M 0.27% 80
2013
Q2
$516M Buy
+8,151,466
New +$530M 0.27% 83

Other funds holding NVS

Wells Fargo's NVS Position: Q1 2026 in Review

Wells Fargo increased its Novartis (NVS) stake by 2.9% in Q1 2026, buying an estimated $8.22M and bringing the position to 1,895,677 shares worth $290M. The position accounts for 0.05% of the portfolio, ranked #287.

Wells Fargo first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $760M in Q2 2015. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Wells Fargo held 1,895,677 shares of Novartis worth $290M as of Q1 2026.
  • Wells Fargo bought 53,634 Novartis shares in Q1 2026, an estimated $8.22M.
  • Novartis made up 0.05% of Wells Fargo's portfolio in Q1 2026, its #287 holding.
  • Wells Fargo first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
  • Wells Fargo's Novartis position peaked at $760M in Q2 2015.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.